EAN 2022 | Concomitant ASM dose reductions in clinical trial of adjunctive cenobamate for focal seizures

Bernhard Steinhoff, MD, PhD, Kork Epilepsy Center, Kehl-Kork, Germany, shares the results of a post-hoc analysis evaluating changes in concomitant antiseizure medication (ASM) drug load and incidence of adverse events from an open-label Phase III study of adjunctive cenobamate (C021; NCT02535091). Patient ASM drug load was quantified using World Health Organization defined daily dose (DDD) at baseline and during post-baseline periods up to 30 months. A reduction in concomitant ASMs DDD in patients with focal epilepsy initiating adjunctive cenobamate was observed, particularly in patients with a high drug load at baseline. This interview took place at the 2022 Congress of the European Academy of Neurology (EAN) in Vienna, Austria.